Stempoint Capital’s UroGen Pharma URGN Stock Holding History

Stempoint Capital’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-241,984	Closed	-$3.07M	–	77
2024 Q3	$3.07M	Buy	+241,984	New	+$3.59M	0.92%	31

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Stempoint Capital's URGN Position: Q4 2024 in Review

Stempoint Capital sold out of UroGen Pharma (URGN) in Q4 2024, closing a stake of 241,984 shares — an estimated $3.07M sold.

Stempoint Capital first reported a position in URGN in Q3 2024 and held it in 1 quarter. The position peaked at $3.07M in Q3 2024. 138 funds tracked by Wall St. Rank hold URGN as of Q4 2024.

Stempoint Capital reported no remaining UroGen Pharma position as of Q4 2024 after selling out during the quarter.
Stempoint Capital sold 241,984 UroGen Pharma shares in Q4 2024, an estimated $3.07M.
Stempoint Capital first reported a position in UroGen Pharma in Q3 2024 and held it in 1 quarter.
Stempoint Capital's UroGen Pharma position peaked at $3.07M in Q3 2024.
138 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2024.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.